Abstract:There are no standards about the delineation of clinical target volume of upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU).This study aims to explore the high-risk local recurrence areas for UTUC patients stratified by primary tumor locations and in order to provide implications for the CTV design. All the UTUC patients who were followed up in our center after radical nephroureterectomy between 2010 and 2016 were retrospectively enrolled. The patterns of first discovered failure were assessed, and local recurrence sites (soft tissue relapse within the retroperitoneal field of exenteration and regional lymph nodes) were evaluated. All of the local recurrence sites were identified by MRI, CT, or PETCT. Three hundred twenty-nine patients with radical nephroureterectomy were enrolled in our study. The median follow up time was 45m (4-110m). Sixty-five patients experienced local recurrence. The median time from surgery to local relapse was 7m (range 1-48m). Local recurrence was the first event in 26 (57.8%) patients, the other 19 patients (42.2%) also had metastasis. We studied the detailed relapse site images of 45 patients. A total of 152 sites of local relapse were observed in 45 patients. The median relapse sites of each patient was 2 (1-10). The average number of positive nodes per patient was 3.4. Among the 152 relapse sites, lymphatic recurrence was the dominant recurrence type (90.1%, 137 sites), and the others were soft tissue recurrence (9.9%, 15 sites). We stratified all the patients into 3 groups according to their tumor location. Para-aorta lymph node region has the highest recurrence rates in all of the patients. The recurrence rates in this region account for 85% in renal pelvic and upper ureter tumor, 75% and 74% in middle and lower ureter tumor. The distribution of recurrent LN in middle and lower ureter tumors were much lower (below mid level of L2) than renal pelvic and upper ureter tumors (superior bonder of L1). Para-aorta recurrence in patients with left-sided UTUC almost occurred in LPA region. While the right-sided UTUC had higher para-aorta recurrence rate in RPC and AC region. Recurrence of internal and external iliac lymph node region was rare (<10%) in all the UTUC patients. In all of the soft tissue recurrence sites, the kidney fossa relapse accounted for 33.3% (5 sites); urecter tumor bed recurrence accounted for 66.7% (10 sites). Lymph node recurrences were the most common recurrence sites in UTUC patients after surgery. Para-aortic lymph node region was the common recurrence lymph regions in UTUC patients. Right-sided UTUC had different local relapse pattern compared with left-sided UTUC in this region. Recurrence in internal and external iliac lymph node region was rare (<10%) in all the UTUC patients. Delineate CTV according to the primary tumor locations can include more than 90% recurrence regions and decrease the radiation areas compared with conventional CTV.

Effectiveness of Adjuvant Radiotherapy for High Recurrence Risk Patients with Upper Tract Urothelial Carcinoma.

Oncological Outcomes of Adjuvant Radiotherapy for Partial Ureterectomy in Distal Ureteral Urothelial Carcinoma Patients

Adjuvant And Salvage Radiotherapy For Urothelial Cell Carcinoma Of Upper Urinary Tract: A Single Institute Experience

Effect of Neoadjuvant Chemotherapy on Locally Advanced Upper Tract Urothelial Carcinoma: a Pooled Analysis.

Real-World Evaluation of Adjuvant Radiotherapy in Upper Tract Urothelial Carcinoma Patients: A Prospective Cohort Study

The application of adjuvant radiotherapy after radical nephroureterectomy in the treatment of upper tract urothelial carcinoma

Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis

Radiation Therapy for Nonmetastatic Medically Inoperable Upper-Tract Urothelial Carcinoma.

Patterns of Local Failure after Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma: Association with Primary Tumor Locations and Implications for the Clinical Target Volume Design of Adjuvant Radiation Therapy

Survival and risk factors among upper tract urothelial carcinoma patients after radical nephroureterectomy in Northeast China

Neoadjuvant Chemotherapy Benefits Survival in High-Grade Upper Tract Urothelial Carcinoma: A Propensity Score-Based Analysis

Pattern and Risk Factors of Local Recurrence after Nephroureterectomy for Upper Tract Urothelial Carcinoma

Risk Factors for Bladder Cancer Recurrence Survival in Patients with Upper-Tract Urothelial Carcinoma

Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis

Impact of tumor architecture on disease recurrence and cancer-specific mortality of upper tract urothelial carcinoma treated with radical nephroureterectomy:

Adjuvant Intraoperative Electron Radiotherapy and External Beam Radiotherapy for Locally Advanced Transitional Cell Carcinoma of the Ureter.

Clinical Efficacy of Adjuvant Chemotherapy in Advanced Upper Tract Urothelial Carcinoma (pT3-T4): Real-World Data from the Taiwan Upper Tract Urothelial Carcinoma Collaboration Group

Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma is Independently Associated with Intravesical Recurrence after Radical Nephroureterectomy

Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with high-risk UTUC.

Exploring Radiotherapy as a Promising Alternative for Managing Advanced Upper Tract Urothelial Carcinoma: Rescuing Chemotherapy-Intolerant Patients

Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Preliminary results from a phase II study.